NCT01634165已完成1 期
Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus® in Healthy Subjects Following Two Single Subcutaneous Doses
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]
研究概览
简要总结
This study involves 2 single injections of LY2963016 and 2 single injections of Lantus. There will be at least 6 days between each injection.
The study will compare LY2963016 to Lantus at two different doses.
This study is approximately 10 weeks long, not including screening. Screening is required within 4 weeks of the start of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males or females
- •Women must be either surgically sterile, post-menopausal, or agree to use a reliable method of birth control during the study
- •Have a body mass index between 18.5 and 29.9 kilograms per meter squared (kg/m²)
- •Are nonsmokers and have not smoked for at least 6 months prior to entering the study
- •Have normal blood pressures and pulse rates at screening, as determined by the investigator
- •Have an electrocardiogram (ECG) at screening considered as within normal limits by the investigator
- •Have clinical laboratory test results within normal reference range for the population
- •Have fasting plasma glucose <110 milligrams per deciliter (mg/dL) (<6.0 micromoles per liter [mmol/L]) at screening
- •Have venous access sufficient to allow for blood sampling, intravenous drug administration, and clamp procedures as per the protocol
- •Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
排除标准
- •Are persons who have previously completed or withdrawn from this study
- •Are currently enrolled in or have discontinued within the last 30 days from a clinical trial involving an investigational drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin
- •Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- •Show evidence of significant active neuropsychiatric disease
- •Show evidence of current use of known drugs of abuse or have a history of use within the past year
- •Have a history of first-degree relatives known to have diabetes mellitus
- •Show evidence of an acute infection with fever or infectious disease at the time of study entry
- •Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies at screening
- •Have positive hepatitis B surface antigens at screening
- •Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement, or birth control methods)
- •Have donated blood or had a blood loss of 450 milliliters (mL) 3 months prior to study enrollment
- •Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to stop alcohol consumption from 48 hours prior to each dosing until discharged from the clinical research unit (CRU)
研究组 & 干预措施
0.3 U/kg LY2963016
Experimental
Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
干预措施: LY2963016 (Drug)
0.3 U/kg Lantus
Experimental
Single 0.3 U/kg subcutaneous dose of Lantus
干预措施: Lantus (Drug)
0.6 U/kg LY2963016
Experimental
Single 0.6 U/kg subcutaneous dose of LY2963016
干预措施: LY2963016 (Drug)
0.6 U/kg Lantus
Experimental
Single 0.6 U/kg subcutaneous dose of Lantus
干预措施: Lantus (Drug)
结局指标
主要结局
Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]
时间窗: Predose up to 24 hours after administration of study drug
Results for LY2936016 treatment arms provide the AUC(0-∞) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-∞) for Lantus.
Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)
时间窗: Predose up to 24 hours after administration of study drug
次要结局
- Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus(Predose up to 24 hours after administration of study drug)
- Total Amount of Glucose Infused (Gtot)(Postdose up to 24 hours after administration of study drug)
- Maximum Glucose Infusion Rate (Rmax)(Postdose up to 24 hours after administration of study drug)
- Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus(Predose up to 24 hours after administration of study drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes MellitusDiabetes Mellitus, Type 1NCT01600950Eli Lilly and Company20
已完成
1 期
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy SubjectsDiabetes MellitusNCT01374178Eli Lilly and Company16
已完成
1 期
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy ParticipantsHealthyNCT01688635Eli Lilly and Company91
已完成
1 期
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy ParticipantsDiabetes MellitusNCT01476345Eli Lilly and Company80
已完成
3 期
A Study in Adults With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01421459Eli Lilly and Company759